STE73-2E9
An anti-RBD (SARS-CoV-2 Spike) antibody.
General information
STE73-2E9 is a human antibody which binds RBD of SARS-CoV-2 Spike protein at the RBD-ACE2 interface. Thereby, it neutralizes (as an IgG) SARS-CoV-2 infection in vitro. It was identified using phage display technique and originated in a SARS-CoV-2-naïve antibody library (Bertoglio et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
Spike protein ACE2 Biophysical assay In vitro Antibody |
in vitro binding assay; in vitro biophysical assay; Vero E6 cells; ACE2-positive Expi293F cells; Calu-3 cells; SARS-CoV-2 strain Münster/FI110320/1/2020 | 12.12 | The antibody (as an IgG) bound RBD in vitro with an EC50 of 0.2 nM (and 0.925 nM binding affinity for the whole SARS-CoV-2 Spike protein). It was observed to bind at the RBD-ACE2 interface. The antibody (as an IgG) neutralized SARS-CoV-2 live virus with an IC50 of 0.43 nM in vitro. |
Mar/11/2021 |
